The overuse of antibiotics is widely recognized as one of the main factors contributing to antimicrobial resistance (AMR), often called the “silent pandemic,” but what is less well-known is that shortages of antibiotics also play a role in fueling it.
Scarce supplies of pediatric amoxicillin, used to treat Strep A, made headlines in the UK late last year, as a surge of infections left at least 19 children dead. From being an outlier, such shortfalls are common and pervasive, affecting countries across the world, and their consequences for individuals’ health and AMR’s spread can be dire.
That is because shortages of first-line antibiotics often lead to overuse of those that are specialized or kept in reserve for emergencies. Not only can these substitutes be less effective, but reliance on them increases the risk of drug resistance developing and infections becoming more difficult to treat in the long-run.
Illustration: Mountain People
Already one of the world’s biggest killers, AMR is on the rise. In 2019, it was directly responsible for an estimated 1.27 million deaths — more than HIV/AIDS and malaria combined — and associated with 4.95 million more.
So far, the global response to this growing crisis has focused mainly on trying to outpace drug-resistant bacteria through the development of new antibiotics.
Yet in the short term, there is ample room to reduce the number of AMR deaths, as well as AMR’s impact on health more broadly, by addressing some of the causes of shortages and improving access to appropriate treatments.
The same market failures that triggered the global AMR crisis are also largely responsible for antibiotic shortages. Compared with other drugs, antibiotics are often more complex and more costly to manufacture, have stricter regulatory requirements and are less profitable. As a result, many pharmaceutical companies have significantly reduced or stopped antibiotic research and development over the past few decades.
Not only are very few new antibiotics being developed, but it has also become less attractive to produce those already on the market, partly due to supply chain bottlenecks and volatility. All it takes is a disruption in the supply of an ingredient or a quality-control problem, or a supplier increasing prices or halting production entirely, to bring the global supply chain of these medicines to a standstill.
Just as important has been the equally volatile demand for antibiotics caused by sudden outbreaks of bacterial infections and poor management of national supplies, which contributes to stockouts. While shortages are not uncommon in the pharmaceutical industry, they are 42 percent more likely for antibiotics than they are for other drugs.
Although precise numbers that would reveal the scale of the problem are difficult to obtain, much of this uncertainty could be avoided with better market intelligence. Even though antibiotics are less lucrative than other drugs, pharmaceutical companies can still turn a profit — if they have accurate data. Improved forecasting can thus reduce risks for manufacturers and provide them with an incentive to scale up production and expand their markets.
There is also plenty of room for improvement in the way that countries — particularly lower-income nations — procure, register and manage these vital drugs.
For example, by expanding the capacity of national regulatory authorities, it would be easier to track and coordinate supplies and create stockpiles to build greater resilience. All of this would also help provide more certainty for drugmakers.
SECURE, an initiative led by the WHO and the Global Antibiotic Research and Development Partnership (of which I am executive director), aims to work with countries to improve access to essential antibiotics. That involves exploring how national regulatory authorities could serve as centralized hubs to help monitor, prevent and respond to shortages.
Eventually, SECURE intends to create more buoyant and competitive markets by encouraging countries to pool procurement, ensuring a more reliable supply.
Shortages of antibiotics are a serious problem for all countries, but there is plenty that can — and should — be done to prevent them. Given the accelerating spread of AMR and the long lead-in time to develop antibiotics, the problem can no longer be overlooked.
Equally important, efforts to address scarce supplies could help ensure that, when new drugs become available, they reach the people who need them.
Manica Balasegaram is executive director of the Global Antibiotic Research and Development Partnership.
Copyright: Project Syndicate
Palauan President Surangel Whipps Jr in a letter to an unnamed US senator on Feb. 9 said that China has offered to “fill every hotel room,” in Palau, “and more if more are built” if the small island nation were to break ties with Taiwan. The letter further claims that China offered US$20 million per year for the creation of a “call center” in Palau, a nation whose economy relies heavily on tourism. It is more evidence that for China, tourism is an economic tool for its political gain. Cleo Paskal, a senior fellow at the Foundation for Defense of Democracies, posted
When Taiwan Semiconductor Manufacturing Co (TSMC) in 2022 unveiled plans to begin building a new chip fabrication facility in Japan and start production this year, it looked like an implausibly aggressive schedule. Chip plants often take three years to complete, and, although the firm had moved faster on its own turf, this would be its first such attempt in Japan — where it would have to navigate foreign bureaucracies and regulations. However, on Saturday, TSMC officially opened its Kumamoto fab, putting it on track to begin mass production later this year. The ribbon cutting marks an early victory for Japan as
When Beijing says “Taiwan has always been an inalienable part of China” and calls this “an indisputable legal and historical fact,” it promotes a claim that has absolutely no basis in international law or history. But by aggressively stating that claim time and again over the years, it has made many in the world believe that fiction, especially when the dominant Western media outlets are reluctant to challenge the Chinese narrative. Indeed, some international publications now use the phrase “reunify” without quotation marks while referring to Beijing’s Taiwan goal. The truth is that Taiwan, for most of its history, had no relationship
At a gathering held by the Chinese Communist Party (CCP) and the Chinese State Council during this year’s Spring Festival, Chinese President Xi Jinping (習近平) reviewed the achievements of the past year. “Good scenery on this side only” (風景這邊獨好), he said about the global situation. The phrase comes from late Chinese leader Mao Zedong’s (毛澤東) poem Qing Ping Le (清平樂), written when he lost power in 1934. It was full of the “Ah-Q” (阿Ｑ) spirit of self-deception. Did Xi not know about this history, or was it a trap laid by his aides? Originally, the Third Plenary Session of the 20th Central